Results · Apr-Jun 2026 · filed 14 Aug 2026
Astal Laboratories Q1 FY27 results
Sales grew 56% to ₹39.5 crore from ₹25.3 crore in Apr-Jun 2025.
Operating profit grew 72% to ₹5.4 crore, an operating margin of 13.7% (up 1.3 points from a year ago).
Net profit grew 77% to ₹3.7 crore from ₹2.1 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales −3%, net profit +241%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 39.5 | 25.3 | +56% |
| Operating profit (EBITDA) | 5.4 | 3.2 | +72% |
| Operating margin | 13.7% | 12.5% | +1.3 pts |
| Net profit | 3.7 | 2.1 | +77% |
Standalone figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
Filings that week
- 16 Aug 2026Announcement under Regulation 30 (LODR)-Newspaper Publication
- 14 Aug 2026Compliances- Statement Of Deviation & Variation
- 14 Aug 2026Results- Financial Results For June 30, 2026
- 14 Aug 2026Board Meeting Outcome for Outcome Of Board Meeting Held On Friday, 14Th August, 2026
From the company's results filed on BSE (Standalone). Business numbers only. Education & analysis, not investment advice or a recommendation.